Clinical evidence supports the integration of dual amylin and calcitonin receptor agonism (DACRA) with GLP-1, GIP and glucagon receptor signaling (triple G) as a synergistic approach for appetite modulation, insulin sensitivity and weight loss. Oban Biopharma Inc. is developing OBT-676, an oral small molecule that delivers full DACRA activity with triple G partial agonism for the treatment of metabolic disorders.